

Biotechnology Fund
SCHEDULE OF INVESTMENTS (Unaudited)

December 31, 2024

	Shares	Value
COMMON STOCKS[†] - 99.9%		
Biotechnology - 75.2%		
Amgen, Inc.	18,507	\$ 4,823,664
Gilead Sciences, Inc.	48,297	4,461,194
Vertex Pharmaceuticals, Inc.*	9,901	3,987,133
Regeneron Pharmaceuticals, Inc.*	5,038	3,588,719
Corteva, Inc.	44,623	2,541,726
Anylam Pharmaceuticals, Inc.*	9,408	2,213,796
Biogen, Inc.*	12,812	1,959,211
Illumina, Inc.*	13,691	1,829,528
Moderna, Inc.*	37,294	1,550,684
Royalty Pharma plc — Class A	59,117	1,508,075
United Therapeutics Corp.*	4,187	1,477,341
BioMarin Pharmaceutical, Inc.*	22,258	1,463,018
Inmed, Inc.*	20,566	1,419,877
Sarepta Therapeutics, Inc.*	11,342	1,379,074
Incyte Corp.*	19,725	1,362,406
Exelixis, Inc.*	36,868	1,227,704
Intra-Cellular Therapies, Inc.*	14,407	1,203,273
Argenx SE ADR*	1,885	1,159,275
REVOLUTION Medicines, Inc.*	25,478	1,114,408
Halozyne Therapeutics, Inc.*	21,195	1,013,333
Legend Biotech Corp. ADR*	29,868	971,905
Roivant Sciences Ltd.*	81,162	960,146
Cytokinetics, Inc.*	20,315	955,618
BioNTech SE ADR*	8,257	940,885
Ionis Pharmaceuticals, Inc.*	26,764	935,669
Blueprint Medicines Corp.*	10,085	879,614
Bridgebio Pharma, Inc.*	31,154	854,866
TG Therapeutics, Inc.*	28,050	844,305
CRISPR Therapeutics AG ^{*1}	21,407	842,579
Crinetics Pharmaceuticals, Inc.*	16,466	841,907
ADMA Biologics, Inc.*	46,121	790,975
Viking Therapeutics, Inc.*	19,483	783,996
Apellis Pharmaceuticals, Inc.*	24,192	771,967
Ultragenyx Pharmaceutical, Inc.*	18,197	765,548
PTC Therapeutics, Inc.*	16,950	765,123
BeiGene Ltd. ADR*	4,071	751,954
Guardant Health, Inc.*	23,844	728,434
Avidity Biosciences, Inc.*	24,298	706,586
Axsome Therapeutics, Inc.*	8,112	686,356
Veracyte, Inc.*	17,192	680,803
Amicus Therapeutics, Inc.*	71,348	672,098
ACADIA Pharmaceuticals, Inc.*	35,302	647,792
Recursion Pharmaceuticals, Inc. — Class A ^{*1}	94,302	637,481
SpringWorks Therapeutics, Inc.*	17,279	624,290
Ideaya Biosciences, Inc.*	23,738	610,067
Denali Therapeutics, Inc.*	29,210	595,300
Nuvalent, Inc. — Class A*	7,513	588,118
Summit Therapeutics, Inc.*	32,604	581,818
Arrowhead Pharmaceuticals, Inc.*	30,893	580,788
Geron Corp.*	163,968	580,447
Iovance Biotherapeutics, Inc.*	78,174	578,488
Arcellx, Inc.*	7,136	547,260
Celldex Therapeutics, Inc.*	20,934	529,002
Dynavax Technologies Corp.*	41,374	528,346
Beam Therapeutics, Inc.*	20,305	503,564
Immunovant, Inc.*	20,015	495,772
Dyne Therapeutics, Inc.*	20,044	472,237
Krystal Biotech, Inc.*	2,988	468,100
Novavax, Inc.*	52,822	424,689
Intellia Therapeutics, Inc.*	35,611	415,224
Total Biotechnology		68,823,556
Pharmaceuticals - 19.7%		
AbbVie, Inc.	42,051	7,472,463
AstraZeneca plc ADR	31,482	2,062,701
Neurocrine Biosciences, Inc.*	11,719	1,599,643
Viatris, Inc.	124,383	1,548,568
Vaxcyte, Inc.*	15,306	1,252,949
Jazz Pharmaceuticals plc*	9,041	1,113,399
Alkermes plc*	34,838	1,001,941
Madrigal Pharmaceuticals, Inc.*	1,856	572,706
Ascendis Pharma A/S ADR*	3,761	517,777
Protagonist Therapeutics, Inc.*	12,753	492,266
Agios Pharmaceuticals, Inc.*	11,893	390,804
Total Pharmaceuticals		18,025,217
Healthcare-Products - 4.0%		
Natera, Inc.*	11,419	1,807,628
Exact Sciences Corp.*	21,939	1,232,752
Twist Bioscience Corp.*	14,484	673,071
Total Healthcare-Products		3,713,451
Healthcare-Services - 1.0%		
Medpace Holdings, Inc.*	2,920	970,111
Total Common Stocks (Cost \$50,136,849)		91,532,335
	Face Amount	
REPURCHASE AGREEMENTS^{††2} - 0.4%		
J.P. Morgan Securities LLC issued 12/31/24 at 4.45% due 01/02/25	\$ 199,423	199,423
BofA Securities, Inc. issued 12/31/24 at 4.43% due 01/02/25	156,755	156,755
Total Repurchase Agreements		356,178

(Cost \$356,178)

356,178

	Shares	
SECURITIES LENDING COLLATERAL^{†,3} - 1.0%		
Money Market Fund^{***}		
First American Government Obligations Fund - Class X, 4.41% ⁴	873,142	873,142
Total Securities Lending Collateral		873,142
(Cost \$873,142)		873,142
Total Investments - 101.3%		
(Cost \$51,366,169)		\$ 92,761,655
Other Assets & Liabilities, net - (1.3)%		(1,212,293)
Total Net Assets - 100.0%		\$ 91,549,362

-
- * Non-income producing security.
 - *** A copy of each underlying unaffiliated fund's financial statements is available at the SEC's website at www.sec.gov.
 - † Value determined based on Level 1 inputs.
 - †† Value determined based on Level 2 inputs.
 - ¹ All or a portion of this security is on loan at December 31, 2024.
 - ² Repurchase Agreements.
 - ³ Securities lending collateral.
 - ⁴ Rate indicated is the 7-day yield as of December 31, 2024.

ADR — American Depositary Receipt
plc — Public Limited Company